Mary Lesperance

4.7k total citations · 1 hit paper
106 papers, 3.4k citations indexed

About

Mary Lesperance is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mary Lesperance has authored 106 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 23 papers in Cancer Research and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mary Lesperance's work include Breast Cancer Treatment Studies (22 papers), Breast Lesions and Carcinomas (18 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Mary Lesperance is often cited by papers focused on Breast Cancer Treatment Studies (22 papers), Breast Lesions and Carcinomas (18 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Mary Lesperance collaborates with scholars based in Canada, United States and Australia. Mary Lesperance's co-authors include Judith D. Toms, Francis Lau, Pauline T. Truong, Michael Downing, Ivo A. Olivotto, Craig Kuziemsky, John D. Kalbfleisch, Caroline Speers, George Downing and Francis Ho and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of the American Statistical Association.

In The Last Decade

Mary Lesperance

106 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PIECEWISE REGRESSION: A TOOL FOR IDENTIFYING ECOLOGICAL THRESHOLDS

2003 800 citations Mary Lesperance et al. profile →

Peers

Countries citing papers authored by Mary Lesperance

Since Specialization

Citations

This map shows the geographic impact of Mary Lesperance's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Lesperance with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Lesperance more than expected).

Fields of papers citing papers by Mary Lesperance

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Lesperance. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Lesperance. The network helps show where Mary Lesperance may publish in the future.

Co-authorship network of co-authors of Mary Lesperance

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Lesperance. A scholar is included among the top collaborators of Mary Lesperance based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Lesperance. Mary Lesperance is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy 2024 ·Targeted Oncology ·Doran Ksienski, Pauline T. Truong, Jeffrey N. Bone, (unknown), (unknown), (unknown), Mary Lesperance, (unknown)	1
2	Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers 2024 ·Journal of Geriatric Oncology ·Doran Ksienski, Pauline T. Truong, Jeffrey N. Bone, (unknown), (unknown), (unknown), Mary Lesperance, (unknown)	3
3	First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic 2023 ·Translational Lung Cancer Research ·(unknown), Pauline T. Truong, Jeffrey N. Bone, Curtis Hughesman, Stephen Yip, Deepu Alex, Jason Hart, Philip H. Pollock, (unknown), (unknown), Mary Lesperance, Doran Ksienski	5
4	Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort 2021 ·Clinical Oncology ·Doran Ksienski, Pauline T. Truong, Elaine S. Wai, Nicole S. Croteau, Angela Chan, (unknown), (unknown), (unknown), (unknown), Mary Lesperance	7
5	Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab 2020 ·Journal of Geriatric Oncology ·Doran Ksienski, Elaine S. Wai, Nicole S. Croteau, (unknown), Angela Chan, (unknown), (unknown), David Fenton, (unknown), (unknown), Mary Lesperance	21
6	Systolic blood pressure as a predictor of transient ischemic attack/minor stroke in emergency department patients under age 80: a prospective cohort study 2019 ·BMC Neurology ·Andrew M. Penn, Nicole S. Croteau, Kristine Votova, (unknown), Robert Balshaw, Shelagh B. Coutts, Melanie Penn, (unknown), (unknown), Viera Saly, Janka Hegedus, Amy Yu, Charlotte Zerna, Evgenia Klourfeld, Mary Lesperance	5
7	P1.01-24 Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated with Prior Radiotherapy 2018 ·Journal of Thoracic Oncology ·Daniel Glick, Elaine S. Wai, Mary Lesperance, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Doran Ksienski	1
8	Transcriptomics investigation of thyroid hormone disruption in the olfactory system of the Rana [Lithobates] catesbeiana tadpole 2018 ·Aquatic Toxicology ·(unknown), Nik Veldhoen, (unknown), (unknown), Linda Li, (unknown), Xiaoyu Zheng, (unknown), Graham van Aggelen, Mary Lesperance, Wayne J. Parker, Eric R. Hall, Greg G. Pyle, Caren C. Helbing	14
9	Differential Proteomics for Distinguishing Ischemic Stroke from Controls: a Pilot Study of the SpecTRA Project 2018 ·Translational Stroke Research ·Andrew M. Penn, Viera Saly, Anurag Trivedi, Mary Lesperance, Kristine Votova, Angela Jackson, Nicole S. Croteau, Robert Balshaw, (unknown), Derek Smith, Karen Lam, (unknown), Linghong Lu, Shelagh B. Coutts, Christoph H. Borchers	17
10	Subventricular Zone Radiation Dose and Outcome for Glioblastoma Treated Between 2006 and 2012 2018 ·Cureus ·(unknown), (unknown), (unknown), (unknown), (unknown), Mary Lesperance, Pauline T. Truong, Abraham Alexander	7
11	Applying STOPP Guidelines in Primary Care Through Electronic Medical Record Decision Support: Randomized Control Trial Highlighting the Importance of Data Quality 2017 ·JMIR Medical Informatics ·Morgan Price, (unknown), (unknown), Mary Lesperance, Jens Weber	26
12	Assessing Conformance with Benford’s Law: Goodness-Of-Fit Tests and Simultaneous Confidence Intervals 2016 ·PLoS ONE ·Mary Lesperance, William J. Reed, Michael A. Stephens, (unknown), (unknown)	23
13	Subsets of Women With Close or Positive Margins After Breast-Conserving Surgery With High Local Recurrence Risk Despite Breast Plus Boost Radiotherapy 2011 ·International Journal of Radiation OncologyBiologyPhysics ·Krystine Lupe, Pauline T. Truong, Cheryl Alexander, Mary Lesperance, Caroline Speers, Scott Tyldesley	37
14	Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence 2010 ·Cancer ·Valérie Panet-Raymond, Pauline T. Truong, Cheryl Alexander, Mary Lesperance, Rachel McDonald, Peter H. Watson	21
15	Independent Validation of IBTR! A Computer-based Tool to Predict Ipsilateral Breast Recurrence in Women with Invasive Breast Cancer Treated with Breast Conserving Surgery 2008 ·International Journal of Radiation OncologyBiologyPhysics ·Pauline T. Truong, Mary Lesperance, (unknown), Stuart Jones, (unknown), David E. Wazer, Ivo A. Olivotto	5
16	In the absence of cancer registry data, is it sensible to assess incidence using hospital separation records? 2006 ·International Journal for Equity in Health ·(unknown), Margaret J. Penning, Mary Lesperance	8
17	Examining Time Intervals Between Diagnosis and Treatment in the Management of Patients With Limited Stage Small Cell Lung Cancer 2006 ·American Journal of Clinical Oncology ·Eric Berthelet, Pauline T. Truong, Mary Lesperance, Jan Lim, Elaine S. Wai, Mary MacNeil, Mitchell Liu, Howard Joe, Ivo A. Olivotto	10
18	Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy 2005 ·International Journal of Radiation OncologyBiologyPhysics ·Pauline T. Truong, Mary Lesperance, (unknown), Hosam A. Kader, Caroline Speers, Ivo A. Olivotto	76
19	Prothrombin Time Determination:The Lack of Need for a Discard Tube and 24-Hour Stability 1997 ·American Journal of Clinical Pathology ·Malcolm L. Brigden, (unknown), (unknown), Mary Lesperance	21
20	A consulting problem involving bivariate acceptance sampling by variables 1991 ·Quality Engineering ·David C. Hamilton, Mary Lesperance	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact